证券代码：603669 证券简称：灵康药业 公告编号：2025-051 灵康药业集团股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 30 日 14 点 30 分 召开地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵 康药业有限公司会议室 股东大会召开日期：2025年7月30日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 30 日 至2025 年 7 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投 ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-052 灵康药业集团股份有限公司 2025 年半年度业绩预告 业绩预告的主要财务数据：公司预计 2025 年半年度实现归属于母公司 所有者的净利润为-3,950 万元到-3,500 万元；归属于母公司所有者的扣除非经 常性损益的净利润为-4,850 万元到-4,400 万元。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 经公司财务部门初步测算，预计 2025 年半年度实现归属于母公司所有者的 净利润为-3,950 万元到-3,500 万元。 预计归属于母公司所有者的扣除非经常性损益的净利润为-4,850 万元到 -4,400 万元。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 业绩预告的适用情形：净利润为负值 （一）利润总额：-4,119.04 万元。归属于母公司所有者的净利润：-4,040.02 万元；归属于母公司所有者的扣除非经常性损益的净利润：-5, ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-049 灵康药业集团股份有限公司 第四届董事会第三十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 1、审议通过了《关于向下修正"灵康转债"转股价格的议案》 灵康药业集团股份有限公司（以下简称"公司"）第四届董事会第三十三次 会议通知于 2025 年 7 月 11 日以电话、电子邮件等形式发出，会议于 2025 年 7 月 14 日在浙江灵康药业有限公司会议室以现场结合通讯方式召开。会议由董事 长陶灵萍召集并主持，应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人。公司监事、高级管理人员列席了会议。本次会议的召集、召开和表决程序符 合有关法律、法规和《公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 灵康药业集团股份有限公司董事会 2025 年 7 月 15 日 2 具体内容详见同日披露于上海证券交易所网站（www.sse.com.cn）的公告。 1 特此公告。 具体内容详见同日披露于上海 ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 转股情况："灵康转债"自 2025 年 4 月 1 日至 2025 年 6 月 30 日期间， 转股的金额为 0 元，因转股形成的股份数量为 0 股，占可转债转股前公司已发行 股份总额的 0.0000%。截至 2025 年 6 月 30 日，累计共有人民币 67,196,000 元 "灵康转债"已转换为公司股票，转股数量为 7,804,755 股，占可转债开始转股 前公司已发行股份总额的 1.0940%。 （五）因"灵康转债" 触发《灵康药业集团股份有限公司公开发行可转换 公司债券募集说明书》中约定的回售条款，公司于 2025 年 4 月 1 日至 2025 年 4 月 8 日进行了回售，回售数量为 10 张，回售资金 ...

Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-046 | | --- | --- | --- | | 证券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 关于不向下修正"灵康转债"转股价格的公告 2、因公司实施 2021 年年度利润分配方案，自 2022 年 7 月 5 日起，转股价 格调整为 8.51 元/股，具体内容详见《关于权益分派引起的"灵康转债"转股价 格调整的公告》（公告编号：2022-042）。 3、因触发"灵康转债"转股价格修正条款，自 2024 年 7 月 16 日起，转股 价格由 8.51 元/股修正为 8.00 元/股，具体内容详见《关于向下修正"灵康转债" 转股价格暨转股停复牌的公告》（公告编号：2024-053）。 二、关于不向下修正转股价格的具体内容 重要内容提示： 截至 2025 年 6 月 23 日，灵康药业集团股份有限公司（以下简称"灵康 药业"或"本公司"）股价已出现连续三十个交 ...

Core Viewpoint - The company, Lingkang Pharmaceutical Group Co., Ltd., has maintained its credit rating for both the company and its convertible bonds, indicating stable financial health and outlook [1][2]. Summary by Relevant Sections Company Credit Rating - The company's credit rating remains at "A-" with a stable outlook, consistent with the previous rating [1][2]. - The last rating was conducted by Dongfang Jincheng International Credit Assessment Co., Ltd. on June 18, 2024 [1]. Convertible Bond Rating - The credit rating for the "Lingkang Convertible Bonds" is also maintained at "A-" with a stable outlook, showing no change from the previous assessment [2].

Group 1 - The company, Lingkang Pharmaceutical Group Co., Ltd., has publicly issued A-share convertible bonds with a total amount of RMB 517.78 million, consisting of 5.25 million bonds at a face value of RMB 100 each [1][4][9] - The bonds are convertible into the company's A-shares, with an initial conversion price set at RMB 8.81 per share, and the conversion period is from June 7, 2021, to November 30, 2026 [2][3][4] - The company has established a special account for the raised funds, which will be used for specific investment projects, including the construction of a production base [9][10][15] Group 2 - In 2024, the company reported a revenue of RMB 379.78 million, a 92.95% increase from RMB 196.83 million in 2023, but incurred a net loss of RMB 130.76 million, an improvement from a loss of RMB 151.50 million in the previous year [12][13] - The total assets decreased by 22.73% to RMB 1.26 billion from RMB 1.62 billion in 2023, and the net assets also fell by 17.32% to RMB 769.76 million [12][13] - The company has terminated the "Hainan Lingkang Pharmaceutical Production Base Construction Project (Phase I)" due to significant changes in project feasibility and will retain the remaining raised funds in the special account [14][15] Group 3 - The company has a credit rating of A- for its bonds as of June 2024, with a stable outlook, reflecting a downgrade from AA- in previous years [12][13] - The company has implemented measures to ensure compliance with regulations regarding the use of raised funds, and there have been no violations reported [10][14] - The company has established a management system for the raised funds, ensuring they are used appropriately for the intended projects [10][14]

Core Viewpoint - The credit rating agency maintains the credit rating of Lingkang Pharmaceutical Group Co., Ltd. at A- with a stable outlook, indicating a consistent assessment of the company's creditworthiness and financial stability [1][4]. Company Overview - Lingkang Pharmaceutical primarily engages in the research, production, and sales of chemical prescription drugs, with a diverse product range including cardiovascular, anti-infection, parenteral nutrition, and digestive system medications [4][12]. - As of March 2025, the company holds a total asset value of 1.23 billion yuan and equity of 0.75 billion yuan, with a debt-to-asset ratio of 39.00% [4][12]. Financial Performance - The company reported a significant increase in operating revenue and gross profit, achieving 3.80 billion yuan in revenue and 1.78 billion yuan in gross profit in 2024, reflecting a substantial year-on-year growth [11][13]. - The gross profit margin for the company was 46.88%, showing a slight decrease compared to previous periods due to pricing pressures from centralized procurement policies [11][13]. Market Position and Strategy - Lingkang's main products include the unique injection of Huperzine A, which maintains a competitive edge in the market, and the company has strengthened its R&D efforts to enhance product quality and clinical application value [4][12]. - The company has adjusted its sales strategy to increase the promotion of centrally procured products and expand sales channels in private hospitals, which has contributed to the growth of its revenue and gross profit [4][13]. Challenges and Risks - The company faces challenges such as low capacity utilization of production lines and ongoing losses in total profit due to the impact of centralized procurement policies on its anti-infection drug profitability [5][12]. - Lingkang has decided to terminate the construction of the "Lingkang Convertible Bond" fundraising project due to changes in industry policies and market conditions, leaving future funding plans uncertain [5][6]. Industry Analysis - The pharmaceutical manufacturing industry in China is experiencing growth driven by increasing demand due to rising disposable income and an aging population, with the industry expected to continue evolving under ongoing policy reforms [8][9]. - The overall revenue of the pharmaceutical manufacturing sector remained stable, while total profits saw a decline, indicating a challenging environment influenced by centralized procurement and pricing regulations [8][9].

Core Viewpoint - The company, Lingkang Pharmaceutical Group Co., Ltd., is set to hold an online performance briefing to discuss its 2024 annual report and 2025 Q1 report, addressing investor concerns and questions [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for June 26, 2025, from 15:00 to 16:00 [4]. - The meeting will take place at the Shanghai Securities News and China Securities Network Roadshow Center, accessible via an online platform [4]. - The format of the meeting will be an interactive text-based online session [3][4]. Group 2: Participation Information - Investors can submit their questions and concerns to the company via fax, phone, or email by June 25, 2025, at 17:30 [5]. - Investors can participate in the briefing on June 26, 2025, by logging into the online platform [5]. Group 3: Contact Information - The company has provided contact persons for inquiries: Sui Guoping and Liao Baoyu, with a contact number and fax number both listed as 0571-81103508 [6]. - An email address for investor relations is also provided: ir@lingkang.com.cn [6]. Group 4: Post-Meeting Access - After the briefing, investors can access the meeting's main content and details through the Shanghai Securities News and China Securities Network Roadshow Center [7].